Next Phase Newsletter

A private equity group based in the Eastern US has around $200 million in assets, and has raised two funds. The firm is currently looking for new opportunities in the life sciences space, and although the firm has no set time frame to make allocations, they are always opportunistically looking to source new investments in the space.

The firm’s typical equity investment size ranges from $10-40 million. Currently, they are most interested in information providers as well as Biotech R&D services firms. In the information provider space, the group is seeking healthcare IT firms, and in the biotech R&D services space, the firm is looking for contract manufacturing organizations (CMOs). The firm solely invests in firms based in North America, and will consider companies headquartered in either the U.S. or Canada.

The firm is looking for companies that have $5-15 million in EBITDA, and $35-100 million in revenue, and $25-125 million in enterprise value, however EBITDA is the most important criteria in terms on the firms investment requirements. Accordingly, the firm does not invest in pre-revenue companies.

Tags: biotech, biotechnology, CMO, consulting, CRO, family offices, Fundraising, investor, Investors, issue, letter, life, Life Science, life science nation, medicine, nation, news, newsletter, pharma, Pharmaceutical, private equity, research & development, science, startup, venture capital

A single-family office based in based in the Eastern US currently manages over $1 billion in total assets, and is seeking to identify new investment opportunities in the life science space. The firm has no set time frame to make an allocation, but would invest in a firm within the next 3-6 months if a compelling opportunity were identified. Because the firm is backed by the founding family, and is not a typical fund that must go through the fundraising cycle, the firm has the ability to deploy capital as soon as an opportunity is sourced. They typically make initial investments in the $500,000 to $1 million range.

The firm is currently most interested in companies in the medical technology space. The firm has no specific areas of interest within the area of medical technology, and thus would be open to considering any kind of medical device.

The firm typically provides growth equity to firms right after they have received their Series A round. They prefer firms that have a pre-money valuation ranging from $3-5 million. The firm has a long-term investment horizon and likes to hold companies in their portfolio for much longer than a typical private equity firm.

Tags: biotech, biotechnology, CMO, consulting, CRO, family offices, Fundraising, investor, Investors, issue, letter, life, Life Science, life science nation, medicine, nation, news, newsletter, pharma, Pharmaceutical, private equity, research & development, science, startup, venture capital

A private equity group based in the Western US has around $100 million in assets, and is currently seeking new investment opportunities in the life sciences space. The firm plans to allocate to around 5-10 companies next year, and typically allocates $1-10 million per firm. The firm is most interested in medtech companies developing medical devices, as well as biotech companies that develop therapeutics.

The firm will only consider firms that currently have products on the market. The firm mainly invests in firms based in the US and Canada, but will also consider firms based in Australia. The firm prefers companies with revenue in the $5-100 million range, and whose enterprise value is less than $100 million. The firm will consider both private & small-cap, publicly owned firms. The firm provides senior secured debt financing to firms and will not take a majority stake in the company.

Tags: biotech, biotechnology, CMO, consulting, CRO, family offices, Fundraising, investor, Investors, issue, letter, life, Life Science, life science nation, medicine, nation, news, newsletter, pharma, Pharmaceutical, private equity, research & development, science, startup, venture capital

A venture capital fund in the Eastern US with around $20 million in total assets is currently looking for new opportunities in the life sciences space. The fund was created by its state legislature to promote economic growth. The organization has an evergreen structure, which means that they provide companies with incremental payments throughout the development phase of the product or company, rather than providing all of the capital to a firm upfront in one lump sum, which is the model that venture capital funds typically follow.

The fund, which is quasi-public, would allocate to a firm within the next six months if a compelling opportunity were identified. The firm’s typical investment size ranges from $300,000-500,000 per firm. Specifically, they are looking for medtech firms developing medical devices. The organization will allocate to firms that are pre-revenue, but the firm does need to have a prototype of the device. Additionally, they are interested in the healthcare/IT space.

Tags: biotech, biotechnology, CMO, consulting, CRO, family offices, Fundraising, investor, Investors, issue, letter, life, Life Science, life science nation, medicine, nation, news, newsletter, pharma, Pharmaceutical, private equity, research & development, science, startup, venture capital

A family office in the Eastern US has over $200 million in total assets under management, and is currently looking for new investments in the life science space, typically investing around $5 million in equity per company. Because the office has an evergreen structure, there is no set timeframe to make an allocation, and thus the firm is always opportunistically sourcing new investment opportunities.
 
The family office is currently looking for new companies in the medtech space. Specifically, they are interested in medical device companies, but have no specific preference in terms of what kind of device the company produces. The family office primarily interested in US or Canadian based firms, however has invested in internationally based companies for add-on acquisitions in the past.
 
The firm primarily engages in buyout transactions, however the firm does sometimes provide growth or venture capital to firms on a case-by-case basis.

Tags: biotech, biotechnology, CMO, consulting, CRO, family offices, Fundraising, investor, Investors, issue, letter, life, Life Science, life science nation, medicine, nation, news, newsletter, pharma, Pharmaceutical, private equity, research & development, science, startup, venture capital

A private equity group based in the Central US has raised three funds, and has around $300 million in total assets under management. The firm is always looking for new opportunities in the life science space, and typically allocates around $20 million per firm ($10 million of the group’s allocation is typically equity, the remainder is financed using debt).
 
The firm is currently most interested in companies within the suppliers and engineering space, as well as biotech R&D service companies. The firm is particularly looking for medical device companies, as well as CMOs and niche chemical production companies. The firm solely invests in US based firms.
 
The PEG is only looking for firms that currently have products that are on the market. Additionally, they are looking for companies that have at least $15-100 million in annualrevenue, and prefer firms with annual EBITDA in the $3-15 million range. Consequently, the firm will not consider early stage pre-revenue companies.

Tags: biotech, biotechnology, CMO, consulting, CRO, family offices, Fundraising, investor, Investors, issue, letter, life, Life Science, life science nation, medicine, nation, news, newsletter, pharma, Pharmaceutical, private equity, research & development, science, startup, venture capital

A nonprofit private equity fund headquartered in the Eastern US has roughly $50 million in assets. The firm’s mission is to create positive social impact via direct investment in several sectors that constitute major areas of concern in third world countries, including healthcare. The PE invests across the life sciences sector, and is always evaluating new opportunities that offer compelling solutions to major public health problems in the developing world. The firm has no set time frame to make an allocation, but would invest if a compelling opportunity were uncovered.
 
The firm makes initial equity investments ranging from $500 thousand to $2 million, with most investments close to the $1 million mark. This capital can be provided as either debt or equity financing. The firm is interested in all areas of the industry, including therapeutics, diagnostics, devices, and service companies (especially CMOs). The firm doesn’t have a specific mandate regarding phase or indication, but prefers later-stage assets. It will however invest in preclinical opportunities with the right co-investor. The firm is comfortable making allocations to companies in the US, Europe or in relevant emerging markets.

Tags: biotech, biotechnology, CMO, consulting, CRO, family offices, Fundraising, investor, Investors, issue, letter, life, Life Science, life science nation, medicine, nation, news, newsletter, pharma, Pharmaceutical, private equity, research & development, science, startup, venture capital